Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric L Simpson

Showing results (251-260 of 315) with videos related to

Pageof 32
Sort By:
Journal of the American Academy of Dermatology|May 18, 2025
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitisRobert Bissonnette, Linda Stein Gold, Leon Kircik, et al.
Dermatology and Therapy|June 23, 2025
Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)Emma Guttman-Yassky, Stephan Weidinger, Eric L Simpson, et al.
Dermatology and Therapy|May 3, 2024
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic DermatitisEric L Simpson, Marjolein de Bruin-Weller, H Chih-Ho Hong, et al.
Journal of the American Academy of Dermatology|February 8, 2018
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose studyEmma Guttman-Yassky, Jonathan I Silverberg, Osamu Nemoto, et al.
Journal of the American Academy of Dermatology|January 31, 2024
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trialEric L Simpson, Jonathan I Silverberg, Margitta Worm, et al.
Trials|July 23, 2017
Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trialJoanne R Chalmers, Rachel H Haines, Eleanor J Mitchell, et al.
JAMA Dermatology|October 1, 2020
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical TrialKristian Reich, Kenji Kabashima, Ketty Peris, et al.
American Journal of Clinical Dermatology|May 14, 2022
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)Andrew Blauvelt, Emma Guttman-Yassky, Amy S Paller, et al.
Advances in Therapy|April 18, 2026
Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension StudyLisa A Beck, Eric L Simpson, Diamant Thaçi, et al.
The British Journal of Dermatology|August 29, 2025
Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of 8 clinical trialsKristian Reich, Richard G Langley, Juan Francisco Silvestre Salvador, et al.
Pageof 32

Showing results (251-260 of 315) with videos related to

Sort By:
Pageof 32
Journal of the American Academy of Dermatology|May 18, 2025
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitisRobert Bissonnette, Linda Stein Gold, Leon Kircik, et al.
Dermatology and Therapy|June 23, 2025
Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)Emma Guttman-Yassky, Stephan Weidinger, Eric L Simpson, et al.
Dermatology and Therapy|May 3, 2024
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic DermatitisEric L Simpson, Marjolein de Bruin-Weller, H Chih-Ho Hong, et al.
Journal of the American Academy of Dermatology|February 8, 2018
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose studyEmma Guttman-Yassky, Jonathan I Silverberg, Osamu Nemoto, et al.
Journal of the American Academy of Dermatology|January 31, 2024
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trialEric L Simpson, Jonathan I Silverberg, Margitta Worm, et al.
Trials|July 23, 2017
Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trialJoanne R Chalmers, Rachel H Haines, Eleanor J Mitchell, et al.
JAMA Dermatology|October 1, 2020
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical TrialKristian Reich, Kenji Kabashima, Ketty Peris, et al.
American Journal of Clinical Dermatology|May 14, 2022
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)Andrew Blauvelt, Emma Guttman-Yassky, Amy S Paller, et al.
Advances in Therapy|April 18, 2026
Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension StudyLisa A Beck, Eric L Simpson, Diamant Thaçi, et al.
The British Journal of Dermatology|August 29, 2025
Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of 8 clinical trialsKristian Reich, Richard G Langley, Juan Francisco Silvestre Salvador, et al.
Pageof 32